Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study
Journal of the American Heart Association · 01.09.2026 · 15 (17)
DOI: 10.1161/jaha.126.049649 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 01.09.2026. Verfasst von Ting-Chun Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine College of Medicine, National Cheng Kung University Tainan Taiwan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Sodium-Glucose Transporter 2 Inhibitors, Ischemic Stroke, Ischemic Attack, Transient. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors reduce incident atrial fibrillation (AF), but their association with cerebrovascular and cardiovascular outcomes after AF diagnosis remains uncertain. We evaluated these outcomes in patients with newly diagnosed AF.
Methods
Using Taiwan's National Health Insurance Research Database, we identified patients with newly diagnosed AF from 2013 through 2022. Regular SGLT2 inhibitor users were propensity score matched 1:10 to nonusers. The primary outcome was a composite of ischemic stroke, hemorrhagic stroke, or transient ischemic attack. Secondary outcomes were all‐cause mortality and major adverse cardiovascular events.
Results
Of 231 030 eligible patients, 20 911 were included in the matched analysis: 1901 users and 19 010 nonusers (mean age, 72 years; 41% women; mean CHA 2 DS 2 ‐VASc score, 3.7). Baseline SGLT2 inhibitor use was not significantly associated with the primary outcome (adjusted hazard ratio [HR], 0.90 [95% CI, 0.70–1.15]; P =0.39), all‐cause mortality (adjusted HR, 0.95 [95% CI, 0.86–1.06]; P =0.38), or major adverse cardiovascular events (adjusted HR, 0.94 [95% CI, 0.84–1.05]; P =0.24). In a time‐dependent sensitivity analysis, current SGLT2 inhibitor exposure was associated with lower all‐cause mortality (adjusted HR, 0.71 [95% CI, 0.63–0.81]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine College of Medicine, National Cheng Kung University Tainan Taiwan.
- Division of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
- Biostatistics Consulting Center National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
- Department of Public Health College of Medicine, National Cheng Kung University Tainan Taiwan.
ORCID-Profile: Ting-Chun Huang, Li-Hao Yap, Hui-Wen Lin, Chao-Yu Chen, Po-Tseng Lee, Sheng-Hsiang Lin, Yi-Heng Li
Zitieren
APA
Huang, T. C., Yap, L. H., Lin, H. W., Su, P. H., Liao, Y., Chen, C. Y., Lee, P. T., Lin, S. H., & Li, Y. H. (2026). Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association, 15(17). https://doi.org/10.1161/jaha.126.049649
Vancouver
Huang TC, Yap LH, Lin HW, Su PH, Liao Y, Chen CY, et al. Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2026;15(17). doi:10.1161/jaha.126.049649
BibTeX
@article{Huang2026,
author = {Huang, Ting-Chun and Yap, Li-Hao and Lin, Hui-Wen and Su, Po-Hsueh and Liao, Yu and Chen, Chao-Yu and Lee, Po-Tseng and Lin, Sheng-Hsiang and Li, Yi-Heng},
title = {Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {17},
doi = {10.1161/jaha.126.049649}
}
EUVIMED